Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Post Anti-PD-(L)1 Non-Small Cell Lung Cancer”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Large-scale testing (Phase 3)Ended earlyNCT05001724
What this trial is testing

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Who this might be right for
Advanced Non-small Cell Lung Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 16
Early research (Phase 1)Study completedNCT04601402
What this trial is testing

GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Who this might be right for
Solid TumorNon Small Cell Lung CancerSquamous Cell Carcinoma of Head and Neck+1 more
Genome & Company 11
Large-scale testing (Phase 3)Active Not RecruitingNCT05450692
What this trial is testing

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Who this might be right for
Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 594
Testing effectiveness (Phase 2)Active Not RecruitingNCT05941897
What this trial is testing

Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy

Who this might be right for
Advanced or Metastatic NSCLC
AstraZeneca 39
Early research (Phase 1)Active Not RecruitingNCT06542731
What this trial is testing

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Ono Pharmaceutical Co., Ltd. 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT05081609
What this trial is testing

Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Who this might be right for
Advanced Solid TumorLocally Advanced Solid TumorMetastatic Solid Tumor+10 more
Ascendis Pharma Oncology Division A/S 320
Large-scale testing (Phase 3)Ended earlyNCT04921358
What this trial is testing

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
BeiGene 377